LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. 

Biotechnology

Education

LEXEO Therapeutics

R. Nolan Townsend

Julie Allen

Rand Monaghan

Emily H.

Amanda Wyatt Anderson

Jenny Speer

Leslie Dirisio

Jordan Dubow

Jenny Robertson

Richie Khanna

Ryan McHenry

Eric Adler

Keith Wonnacott

Ronald Crystal

Paul B. McCormac

The Leadership Team at LEXEO Therapeutics is responsible for guiding the strategic direction of the company and ensuring alignment across various functions, including legal, regulatory, technical, and scientific disciplines. This team collaborates to drive innovation in gene therapy, oversee the development of the therapeutic pipeline, and navigate complex regulatory landscapes, all while fostering a culture of excellence and advancing the company's mission to combat genetic and acquired diseases.

Leadership Team

Clinical Development Team

Research and Development

Leadership Team

About

Team members

Other teams at LEXEO Therapeutics

Clinical Development Team

Research and Development